Janssen Pharmaceutical K.K.
Clinical trials sponsored by Janssen Pharmaceutical K.K., explained in plain language.
The Japanese subsidiary of Janssen, a pharmaceutical arm of Johnson & Johnson.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Experimental gene therapy aims to halt vision loss in rare eye disease Results expected Jun 2027 (estimated)
-
New pill shows promise for rare, severe psoriasis
Disease control OngoingThis phase 3 trial tests an oral drug called JNJ-77242113 in 19 people with two rare and severe forms of psoriasis: generalized pustular psoriasis and erythrodermic psoriasis. The study measures how many participants see improvement after 16 weeks of treatment. It is an open-labe…
Phase 3 • Sponsor: Janssen Pharmaceutical K.K. • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New drug combo shows promise for rare salivary gland cancer
Disease control OngoingThis study tests whether a combination of two hormone-blocking drugs (apalutamide and a GnRH agonist) can shrink or slow the growth of advanced salivary gland cancer that has a specific protein called the androgen receptor. About 31 adults with locally advanced or spread cancer t…
Phase 2 • Sponsor: Janssen Pharmaceutical K.K. • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New bladder cancer drug delivery system tested in small japanese study
Disease control OngoingThis early-stage study tests a new treatment called TAR-210 in 5 Japanese patients with a type of bladder cancer that has specific genetic changes (FGFR mutations). The treatment is placed directly into the bladder to deliver the drug erdafitinib. The main goal is to see if it is…
Phase 1 • Sponsor: Janssen Pharmaceutical K.K. • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Experimental gene therapy aims to halt vision loss in rare eye disease
Disease control OngoingThis Phase 3 study tests a gene therapy called AAV5-hRKp.RPGR in 4 Japanese people with X-linked retinitis pigmentosa, a genetic condition that causes progressive vision loss. The therapy is injected into the eye to deliver a working copy of the RPGR gene. The main goal is to che…
Phase 3 • Sponsor: Janssen Pharmaceutical K.K. • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC